ValuEngine downgraded shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) from a hold rating to a sell rating in a report published on Friday morning.

Separately, Piper Jaffray Companies reiterated an overweight rating and issued a $6.00 price objective on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.

Shares of Aptevo Therapeutics (NASDAQ:APVO) opened at $2.64 on Friday. Aptevo Therapeutics has a 52-week low of $1.15 and a 52-week high of $3.85. The company has a current ratio of 5.66, a quick ratio of 4.98 and a debt-to-equity ratio of 0.36.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/14/aptevo-therapeutics-inc-apvo-lowered-to-sell-at-valuengine.html.

A number of institutional investors have recently modified their holdings of APVO. Spark Investment Management LLC grew its position in Aptevo Therapeutics by 167.4% in the second quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 38,500 shares during the period. Legal & General Group Plc grew its position in Aptevo Therapeutics by 11,751.3% in the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after acquiring an additional 390,379 shares during the period. Precept Management LLC purchased a new position in Aptevo Therapeutics in the second quarter worth approximately $1,210,000. Finally, Dimensional Fund Advisors LP grew its position in Aptevo Therapeutics by 8.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after acquiring an additional 78,109 shares during the period. Institutional investors own 39.19% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related stocks with our FREE daily email newsletter.